Did you know? You can suggest edits to improve this peptide information.
Overview
What is Bromantane (Ladasten)?
Bromantane (Ladasten) is a unique adamantane derivative and actoprotector developed in the 1980s at the Zakusov State Institute of Pharmacology in Russia, originally field-tested by the Soviet military in Afghanistan for heat stress and marching fatigue. Unlike traditional stimulants that work through receptor agonism or reuptake inhibition, bromantane enhances dopamine and serotonin synthesis by upregulating the gene expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) — the rate-limiting enzymes in catecholamine production. It also strengthens GABAergic signaling by reducing GABA transporter expression, producing anxiolytic effects without sedation. Approved in Russia in 1997 for the treatment of asthenic disorders (neurasthenia), it uniquely combines stimulant and anxiolytic properties without tolerance, dependence, or withdrawal. A landmark 728-patient clinical trial demonstrated a 76% response rate with only 3% side effects.
Key Benefits
Unique dual stimulant-anxiolytic action, 42% oral bioavailability, no tolerance or dependence, 76% clinical response rate, sustained benefits up to 1 month post-discontinuation, enhanced physical performance under stress, immunostimulatory effects
Mechanism of Action
Bromantane penetrates neuronal nuclei and promotes demethylation of CpG islands in TH and AADC gene promoter regions, exposing binding sites for transcription factors (CREB, AP2). This induces mRNA synthesis for dopamine and serotonin biosynthetic enzymes — TH mRNA reaches 220% in VTA within 1 hour, with 2-2.5x upregulation in hypothalamus by 1.5-2 hours. Additionally, bromantane reduces GABA transporter (GAT) expression, decreasing GABA reuptake and strengthening GABAergic signaling for anxiolytic effects without sedation. Sustained genomic upregulation over 7-14 days creates stable neurotransmitter enhancement fundamentally different from traditional stimulants.
Molecular Information
Weight
306.24 Da
Length
Small molecule (adamantane derivative)
Type
N-(4-Bromophenyl)adamantan-2-amine
Amino Acid Sequence:
C16H20BrN (not a peptide — synthetic small molecule)
* Adamantane scaffold with para-bromophenyl amine substitution at C-2 position
Research Indications
Motivation and Drive Enhancement
Sustained dopamine synthesis upregulation provides stable motivational enhancement without the peaks and crashes of reuptake inhibitors. Effects build over 7-14 days and persist after discontinuation.
Anti-Fatigue / Anti-Asthenia
Approved in Russia for asthenic disorders (neurasthenia). 728-patient trial demonstrated 76% response rate with significant improvements in energy, motivation, and cognitive function.
Cognitive Clarity Under Stress
Actoprotector class — enhances mental and physical performance under conditions of stress, fatigue, and environmental challenge without cardiovascular strain.
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Morning dosing is preferred to align with circadian dopamine production. The 11-hour half-life provides all-day coverage. Take 1-2 hours before demanding cognitive or physical tasks for acute benefits on top of chronic gene expression effects.
Peptide Interactions
How to Take
Take capsule or measured powder dose in the morning with water
Can be taken with or without food — food may slow but not reduce absorption
For powder: measure precisely with milligram scale due to low dose ranges
Maintain consistent daily timing for optimal gene expression effects
Full therapeutic effects develop over 7-14 days of consistent dosing
Store in cool, dry place at room temperature away from light and moisture
Quality Indicators
White to off-white crystalline powder
High-quality bromantane should be a white to slightly off-white crystalline solid without discoloration or strong odor
Third-party purity testing
Certificate of analysis showing ≥98% purity via HPLC, with identity confirmed by mass spectrometry (MW 306.24)
Proper packaging
Sealed containers with desiccant, batch numbers, and clear labeling. Bromantane is lipophilic and should be protected from moisture.
Research chemical status (US/EU)
Not FDA/EMA approved. Only available through research chemical suppliers or international pharmacies. Quality varies significantly between vendors.
WADA prohibited substance
Banned by WADA since 1997. Athletes subject to anti-doping testing must avoid bromantane. Metabolites detectable up to 14 days.
Yellowing or clumping
Discoloration indicates degradation. Excessive moisture absorption (clumping) compromises the compound.
What to Expect
- Day 1-3: Subtle stimulation and mood lift within 1.5-2 hours of dosing. Mild increase in motivation and energy.
- Week 1: Noticeable improvement in baseline energy, reduced mental fatigue, emerging anxiolytic effects.
- Week 2-3: Full therapeutic effects as TH/AADC gene expression reaches peak upregulation. Sustained motivation without peaks/crashes.
- Week 3-4: Maximal benefits — stable mood, physical endurance, cognitive clarity under stress, anxiety reduction.
- Post-cycle: Benefits persist 2-4 weeks after discontinuation due to sustained enzyme expression changes.
- Notable: No tolerance development — effects remain consistent throughout cycle without dose escalation.
Side Effects & Safety
- Exceptionally safe profile: LD50 of 9000 mg/kg in rats (90-180x therapeutic dose equivalent)
- 728-patient trial showed only 3% side effects and 0.8% discontinuation rate
- No tolerance, dependence, or withdrawal documented in clinical use
- Not FDA/EMA approved — use under personal discretion with medical supervision
- Avoid combining with MAOIs — theoretical risk of neurotransmitter accumulation based on mechanism (no clinical cases documented)
- Monitor if combining with SSRIs — theoretical concern for metabolic interactions through shared hepatic pathways
- Highly lipophilic — accumulates in adipose tissue, meaning effects and metabolite detection persist longer than half-life suggests
- Anticholinergic effects only observed at extreme supratherapeutic doses (>600mg/kg in animals) — not relevant at clinical doses
References
Multicenter Asthenia Clinical Trial (2009)
Landmark Russian multicenter trial demonstrating 76% response rate on CGI-S (Clinical Global Impression - Severity) and 90.8% improvement on CGI-I (Clinical Global Impression - Improvement). Only 3% experienced side effects with 0.8% discontinuation rate, establishing an exceptional safety-to-efficacy ratio.
View Study (opens in new tab) →Tyrosine Hydroxylase Gene Expression Study (2007)
Demonstrated that bromantane increases tyrosine hydroxylase (TH) mRNA expression 2-2.5 fold in the rat hypothalamus and striatum, confirming its unique mechanism of enhancing dopamine synthesis at the gene expression level rather than through receptor modulation.
View Study (opens in new tab) →Pharmacokinetic Profile Study
Established key pharmacokinetic parameters: 42% oral bioavailability, half-life of 11.21 hours, Tmax of 2.75 hours in females and 4 hours in males. Primary metabolite 6β-hydroxybromantane detected in urine up to 2 weeks post-administration due to lipophilic tissue deposition.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia